TapewireFind a company

person · Reporting owner

WILLIAMS KRISTEN

Disclosed activity across 1 company

Tapewire entity
40880
SEC CIK
0001296965

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Pacira BioSciences, Inc.PCRX · Entity 4928Chief Administrative OfficerJune 03, 2026June 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Pacira BioSciences, Inc.

Report date June 03, 2026 · Filed June 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect167,062 Ending reported balance After 2026-06-04 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-06-03 · Tax withholding · Disposed 8,528 · Balance 177,321

F1: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Row 2 · 2026-06-04 · Sale · Disposed 10,259 · Balance 167,062

F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 04, 2026 Filed Jun 5, 2026 21:57 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 10,259 $22.27 $228,467.93
Disclosure

SEC source: 0001628280-26-041330 · wk-form4_1780696617.xml · nonDerivative · entry 2

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 167,062

F2 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025.

Read SEC document
June 03, 2026 Filed Jun 5, 2026 21:57 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Tax withholdingCommon Stock 8,528 $22.32 $190,344.96
Disclosure

SEC source: 0001628280-26-041330 · wk-form4_1780696617.xml · nonDerivative · entry 1

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,321

F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:02 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 GrantCommon Stock 54,546 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-008078 · wk-form4_1771016534.xml · nonDerivative · entry 1

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,849

F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
February 02, 2026 Filed Feb 3, 2026 23:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 13,137 $20.53 $269,702.61
Disclosure

SEC source: 0001628280-26-005157 · wk-form4_1770161039.xml · nonDerivative · entry 2

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 131,303

F2 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
January 30, 2026 Filed Feb 3, 2026 23:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Tax withholdingCommon Stock 17,134 $20.54 $351,932.36
Disclosure

SEC source: 0001628280-26-005157 · wk-form4_1770161039.xml · nonDerivative · entry 1

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,440

F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 21:37 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 14,376 $26.24 $377,226.24
Disclosure

SEC source: 0001396814-25-000068 · wk-form4_1749159376.xml · nonDerivative · entry 2

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,574

Read SEC document
June 03, 2025 Filed Jun 5, 2025 21:37 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Tax withholdingCommon Stock 6,162 $26.40 $162,676.80
Disclosure

SEC source: 0001396814-25-000068 · wk-form4_1749159376.xml · nonDerivative · entry 1

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,950

F1 · kind: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Read SEC document
February 01, 2025 Filed Feb 4, 2025 23:25 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 GrantCommon Stock 79,200 $0.00 $0.00
Disclosure

SEC source: 0001396814-25-000032 · wk-form4_1738711548.xml · nonDerivative · entry 1

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,112

F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 1, 2026, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 13, 2024 Filed Jun 13, 2024 22:12 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 7,452 $28.38 $211,487.76
Disclosure

SEC source: 0001396814-24-000074 · wk-form4_1718316760.xml · nonDerivative · entry 2

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,912

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
June 12, 2024 Filed Jun 13, 2024 22:12 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 GrantCommon Stock 54,300 $0.00 $0.00
Disclosure

SEC source: 0001396814-24-000074 · wk-form4_1718316760.xml · nonDerivative · entry 1

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,364

F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 03, 2024 Filed Jun 5, 2024 21:09 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Tax withholdingCommon Stock 3,011 $30.89 $93,009.79
Disclosure

SEC source: 0001396814-24-000053 · wk-form4_1717621763.xml · nonDerivative · entry 1

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,064

F1 · kind: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Read SEC document
February 05, 2024 Filed Feb 7, 2024 21:59 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 GrantCommon Stock 33,700 $0.00 $0.00
Disclosure

SEC source: 0001396814-24-000018 · wk-form4_1707343183.xml · nonDerivative · entry 1

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,075

F1 · shares: Represents restricted stock units that vest on February 1, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:42 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 GrantStock Option (Right to Buy) · Derivative 27,500 $0.00 Strike: $38.74 $0.00
Disclosure

SEC source: 0001209191-23-038032 · doc4.xml · derivative · entry 3

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,500

Underlying: Common Stock · 27,500 shares

Expires 2033-06-14

F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:42 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 6,467 $37.03 $239,473.01
Disclosure

SEC source: 0001209191-23-038032 · doc4.xml · nonDerivative · entry 2

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,375

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:42 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 GrantCommon Stock 10,950 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-038032 · doc4.xml · nonDerivative · entry 1

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,842

F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2024, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 07, 2023 Filed Jun 8, 2023 01:34 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 1,357 $37.87 $51,382.81
Disclosure

SEC source: 0001209191-23-035265 · doc4.xml · nonDerivative · entry 2

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,892

F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

Read SEC document
June 06, 2023 Filed Jun 8, 2023 01:34 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 1,301 $38.99 $50,727.29
Disclosure

SEC source: 0001209191-23-035265 · doc4.xml · nonDerivative · entry 1

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,249

F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

Read SEC document
June 08, 2022 Filed Jun 8, 2022 23:46 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 GrantStock Option (Right to Buy) · Derivative 24,800 $0.00 Strike: $59.39 $0.00
Disclosure

SEC source: 0001209191-22-035233 · doc4.xml · derivative · entry 4

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,800

Underlying: Common Stock · 24,800 shares

Expires 2032-06-08

F4 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
June 08, 2022 Filed Jun 8, 2022 23:46 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 GrantCommon Stock 9,900 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-035233 · doc4.xml · nonDerivative · entry 3

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,550

F3 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 07, 2022 Filed Jun 8, 2022 23:46 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 4,649 $59.51 $276,661.99
Disclosure

SEC source: 0001209191-22-035233 · doc4.xml · nonDerivative · entry 2

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,650

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
June 06, 2022 Filed Jun 8, 2022 23:46 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 3,969 $61.37 $243,593.41
Disclosure

SEC source: 0001209191-22-035233 · doc4.xml · nonDerivative · entry 1

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,299

F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

Read SEC document
March 21, 2022 Filed Mar 23, 2022 20:37 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 2,188 $0.00 Strike: $47.65 $0.00
Disclosure

SEC source: 0001209191-22-020788 · doc4.xml · derivative · entry 7

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,685

Underlying: Common Stock · 2,188 shares

Expires 2030-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
March 21, 2022 Filed Mar 23, 2022 20:37 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 2,112 $0.00 Strike: $43.54 $0.00
Disclosure

SEC source: 0001209191-22-020788 · doc4.xml · derivative · entry 6

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,560

Underlying: Common Stock · 2,112 shares

Expires 2029-06-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
March 21, 2022 Filed Mar 23, 2022 20:37 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 2,953 $0.00 Strike: $38.35 $0.00
Disclosure

SEC source: 0001209191-22-020788 · doc4.xml · derivative · entry 5

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,953

Underlying: Common Stock · 2,953 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
March 21, 2022 Filed Mar 23, 2022 20:37 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 7,253 $72.67 $527,075.51
Disclosure

SEC source: 0001209191-22-020788 · doc4.xml · nonDerivative · entry 4

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,268

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
March 21, 2022 Filed Mar 23, 2022 20:37 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 2,188 $47.65 $104,258.20
Disclosure

SEC source: 0001209191-22-020788 · doc4.xml · nonDerivative · entry 3

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,521

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
March 21, 2022 Filed Mar 23, 2022 20:37 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 2,112 $43.54 $91,956.48
Disclosure

SEC source: 0001209191-22-020788 · doc4.xml · nonDerivative · entry 2

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
March 21, 2022 Filed Mar 23, 2022 20:37 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 2,953 $38.35 $113,247.55
Disclosure

SEC source: 0001209191-22-020788 · doc4.xml · nonDerivative · entry 1

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,221

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
February 25, 2022 Filed Mar 1, 2022 22:43 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 2,050 $0.00 Strike: $38.35 $0.00
Disclosure

SEC source: 0001209191-22-014194 · doc4.xml · derivative · entry 7

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,906

Underlying: Common Stock · 2,050 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
February 25, 2022 Filed Mar 1, 2022 22:43 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 2,000 $67.07 $134,140.00
Disclosure

SEC source: 0001209191-22-014194 · doc4.xml · nonDerivative · entry 5

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,268

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.015 to $67.160, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
February 25, 2022 Filed Mar 1, 2022 22:43 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 50 $65.00 $3,250.00
Disclosure

SEC source: 0001209191-22-014194 · doc4.xml · nonDerivative · entry 4

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,268

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
February 25, 2022 Filed Mar 1, 2022 22:43 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 2,050 $38.35 $78,617.50
Disclosure

SEC source: 0001209191-22-014194 · doc4.xml · nonDerivative · entry 3

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,318

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
February 16, 2022 Filed Mar 1, 2022 22:43 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 10 $0.00 Strike: $38.35 $0.00
Disclosure

SEC source: 0001209191-22-014194 · doc4.xml · derivative · entry 6

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,956

Underlying: Common Stock · 10 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
February 16, 2022 Filed Mar 1, 2022 22:43 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 10 $65.00 $650.00
Disclosure

SEC source: 0001209191-22-014194 · doc4.xml · nonDerivative · entry 2

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,268

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
February 16, 2022 Filed Mar 1, 2022 22:43 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 10 $38.35 $383.50
Disclosure

SEC source: 0001209191-22-014194 · doc4.xml · nonDerivative · entry 1

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,278

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
February 10, 2022 Filed Feb 14, 2022 22:12 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 800 $0.00 Strike: $38.35 $0.00
Disclosure

SEC source: 0001209191-22-009400 · doc4.xml · derivative · entry 3

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,966

Underlying: Common Stock · 800 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
February 10, 2022 Filed Feb 14, 2022 22:12 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 800 $65.18 $52,144.00
Disclosure

SEC source: 0001209191-22-009400 · doc4.xml · nonDerivative · entry 2

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,268

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.10 to $65.32, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
February 10, 2022 Filed Feb 14, 2022 22:12 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 800 $38.35 $30,680.00
Disclosure

SEC source: 0001209191-22-009400 · doc4.xml · nonDerivative · entry 1

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,068

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
February 04, 2022 Filed Feb 8, 2022 21:25 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 1,000 $0.00 Strike: $38.35 $0.00
Disclosure

SEC source: 0001209191-22-007755 · doc4.xml · derivative · entry 3

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,766

Underlying: Common Stock · 1,000 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
February 04, 2022 Filed Feb 8, 2022 21:25 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 1,000 $65.18 $65,180.00
Disclosure

SEC source: 0001209191-22-007755 · doc4.xml · nonDerivative · entry 2

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,268

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.045 to $65.330, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
February 04, 2022 Filed Feb 8, 2022 21:25 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 1,000 $38.35 $38,350.00
Disclosure

SEC source: 0001209191-22-007755 · doc4.xml · nonDerivative · entry 1

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,268

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
January 21, 2022 Filed Jan 25, 2022 21:36 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 200 $0.00 Strike: $38.35 $0.00
Disclosure

SEC source: 0001209191-22-004795 · doc4.xml · derivative · entry 3

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,766

Underlying: Common Stock · 200 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
January 21, 2022 Filed Jan 25, 2022 21:36 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 200 $65.41 $13,082.00
Disclosure

SEC source: 0001209191-22-004795 · doc4.xml · nonDerivative · entry 2

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,268

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.365 to $65.460, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
January 21, 2022 Filed Jan 25, 2022 21:36 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 200 $38.35 $7,670.00
Disclosure

SEC source: 0001209191-22-004795 · doc4.xml · nonDerivative · entry 1

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,468

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
January 19, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 2,199 $0.00 Strike: $38.35 $0.00
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · derivative · entry 13

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,966

Underlying: Common Stock · 2,199 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
January 19, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 2,199 $65.51 $144,056.49
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 8

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,268

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.055 to $65.880, inclusive.

Read SEC document
January 19, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 2,199 $38.35 $84,331.65
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 7

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
January 18, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 13,127 $0.00 Strike: $47.65 $0.00
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · derivative · entry 12

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,873

Underlying: Common Stock · 13,127 shares

Expires 2030-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
January 18, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 6,338 $0.00 Strike: $43.54 $0.00
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · derivative · entry 11

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,672

Underlying: Common Stock · 6,338 shares

Expires 2029-06-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
January 18, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 2,600 $0.00 Strike: $38.35 $0.00
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · derivative · entry 10

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,165

Underlying: Common Stock · 2,600 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.